CORDIS · 248289 · FP7
BCELLSMICETOMEN Translational study on the antigen presenting properties of human vs mouse B cell subpopulations
Coordinator: THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES (BG)
Our recent results on antitumor effects of carbohydrate mimotope peptides (CMP) suggest a possible role of carbohydrate reactive B cell subpopulations as cellular adjuvants. As an abundant alternative of dendritic cells, CD40-activated B cells can efficiently present specific antigens being expandable for several weeks. Some B cells can be sufficiently detrimental to warrant anti-B cell therapy in cancer. Other (mouse) B cell subsets (e.g. B1 and marginal zone (MZ) B cells) seem as effective as mature DC, including skewing the T cell to the desirable Th1 responses. Thus, B subpopulations dese…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €75k awarded to the consortium. The project runs over approximately 3 years from 2010-04-15 to 2013-04-14.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from BG
see all →- H2START — Green Innovations in Hydrogen for Sustainable Energy Transition101136692 · HORIZON · €15.0M
- PlantaSYST — Establishment of a Center of Plant Systems Biology and Biotechnology for the translation of fundamental research into sustainable bio-based technologies in Bulgaria739582 · H2020 · €14.9M
- BRAIN PP — Bulgarian Robotics & AI Nexus - Where Human Ingenuity meets Artificial Intelligence101250707 · HORIZON · €10.0M
- ODYSSEUS — PREVENTING, COUNTERING, AND INVESTIGATING TERRORIST ATTACKS THROUGH PROGNOSTIC, DETECTION, AND FORENSIC MECHANISMS FOR EXPLOSIVE PRECURSORS101021857 · H2020 · €5.0M
- VELES — VELES Excellence Hub - Strengthening the South-East Europe Smart Health Regional Excellence and Boosting the Innovation Potential101087483 · HORIZON · €4.8M
- INERA — Research and Innovation Capacity Strengthening of ISSP-BAS in Multifunctional Nanostructures316309 · FP7 · €4.1M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the MC-IRG funding scheme.
- What is the EU contribution?
- The European Commission contributes €75k toward a total project budget of €75k.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES (BG).
- What is the project timeline?
- The project runs from 2010-04-15 to 2013-04-14 — approximately 3 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 248289.